Argenica Therapeutics

Dr Liz Dallimore

CEO & Managing Director

New investors

Updates

Home

Announcements

Lora

Why Argenica Therapeutics?

Welcoming our existing shareholders and new and potential shareholders to Argenica’s Investor Hub. For those of you new to the Argenica Therapeutics story, we are a clinical stage drug development company, developing novel treatments that aim to protect brain cells following injury.

There is currently a huge medical need for a safe therapeutic drug that provides protection to brain cells following acute brain injury such as after a stroke, traumatic brain injury and hypoxic ischemic encephalopathy. Further, chronic neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease could hugely benefit from a neuroprotective therapeutic.

Here at Argenica, we are taking pioneering research from the Perron Institute of Neurological and Translational Science and the University of Western Australia and developing a clinical program for our lead drug candidate, ARG-007, to find a treatment for these devastating neurological conditions.

We are one of only a few companies globally that is progressing into human patient clinical trials for a neuroprotective drug, therefore opening up a huge opportunity for the Company and our shareholders.

We invite you to take a look around our Investor Hub and use it as an opportunity to engage with the Company and stay abreast of all the exciting work we are undertaking.

Thank you for your ongoing support and we look forward to keeping you abreast of our progress.